[
 {
  "trial": "T013",
  "source": "registry",
  "arms": {
   "Ketamine Group": {
    "randomized": "6",
    "analysed": "0"
   },
   "No ketamine group": {
    "randomized": "6",
    "analysed": "0"
   }
  },
  "depression": [],
  "pain": [],
  "adverse_events": [
   {
    "window": "overall",
    "values": {
     "Ketamine Group": {
      "any_ae": "0"
     },
     "No ketamine group": {
      "any_ae": "0"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": null,
  "registration": {
   "number": "NCT02422303",
   "date": null
  },
  "note": "Registry posted results only. The primary outcome (Goldberg Depression Screening Test, one week) lists 'Analysed: Ketamine Group: 0; No Ketamine Group: 0' and no values, so there is no depression entry and analysed is 0. Randomized taken from participant flow STARTED 6/6 (COMPLETED 5/5, NOT COMPLETED 1/1). Adverse events module: serious 0/6 and other 0/6 in each arm; any_ae '0' records that neither kind was posted, not a printed 'any adverse event' count. The registry spells the control arm 'No Ketamine Group'. No enrollment dates given."
 },
 {
  "trial": "T014",
  "source": "abstract",
  "arms": {
   "Group K": {
    "randomized": null,
    "analysed": null
   },
   "Group C": {
    "randomized": null,
    "analysed": null
   }
  },
  "depression": [],
  "pain": [
   {
    "measure": "VAS pain in PACU, at 4 h, 24 h and days 2-5",
    "day": 1,
    "form": "mean_sd",
    "location": "abstract, Results (24 h value)",
    "values": {
     "Group K": {
      "mean": "2.4",
      "sd": "0.5"
     },
     "Group C": {
      "mean": "2.6",
      "sd": "0.5"
     }
    }
   },
   {
    "measure": "VAS pain in PACU, at 4 h, 24 h and days 2-5",
    "day": 2,
    "form": "mean_sd",
    "location": "abstract, Results ('2 d after surgery' value)",
    "values": {
     "Group K": {
      "mean": "2.0",
      "sd": "0.4"
     },
     "Group C": {
      "mean": "2.3",
      "sd": "0.5"
     }
    }
   }
  ],
  "adverse_events": [],
  "blinding_check": null,
  "enrollment": {
   "start": "2015-06",
   "end": "2016-05"
  },
  "registration": null,
  "note": "Abstract only. 66 patients randomized in total; per-arm numbers not given (by 6 months 2 lost in group C, 1 in group K). VAS values are listed in the order 'PACU, 4 h, 24 h and 2-5 d': group K (2.5±0.8), (2.4±0.5), (2.4±0.5), (2.0±0.4), (1.5±0.5), (1.0±0.4), 1(1); group C (2.9±1.0), (2.9±0.6), (2.6±0.5), (2.3±0.5), (1.8±0.6), (1.5±0.5), 1(0). 24 h is day 1 and '2 d after surgery' day 2; '±' is not defined in the abstract and is read as mean ± SD. HADS (preoperative, day 5, 3 and 6 months) is reported only as significance statements, with no numbers. Analgesic consumption only as 'lower ... (all P<0.05)'. PMPS incidence at 3 and 6 months (25% and 22% vs 52% and 45%) is outside the day 1-2 pain window. No adverse events reported. Enrollment period from the abstract's Methods ('From June 2015 to May 2016')."
 },
 {
  "trial": "T025",
  "source": "abstract",
  "arms": {
   "Ketamine": {
    "randomized": null,
    "analysed": "41"
   },
   "Normal saline": {
    "randomized": null,
    "analysed": "43"
   }
  },
  "depression": [
   {
    "measure": "Montgomery-Asberg Depression Rating Scale",
    "day": 3,
    "form": "count",
    "definition": "treatment response: ≥50% reduction from the baseline MADRS score (events are responders, not participants with depression)",
    "location": "abstract, Results",
    "values": {
     "Ketamine": {
      "events": "17",
      "n": "41"
     },
     "Normal saline": {
      "events": "7",
      "n": "43"
     }
    }
   }
  ],
  "pain": [],
  "adverse_events": [],
  "blinding_check": null,
  "enrollment": null,
  "registration": null,
  "note": "Abstract only. 84 patients enrolled; per-arm randomized numbers are not stated (the response denominators 41 and 43 are recorded as analysed). The day-3 entry counts responders (41.5% [17/41] vs 16.3% [7/43]; RR 2.51, 95% CI 1.18-5.50), so a higher count favours the arm, the reverse of a depression count. Remission at discharge, day not given and remission not defined: 29.3% [12/41] vs 7.0% [3/43]; RR 4.20, 95% CI 1.28-13.80 (not entered because its day is unknown). No MADRS means and no baseline values. Adverse events only as 'No psychotic symptoms or adverse events were reported to be substantially higher in the ketamine group' (no counts)."
 },
 {
  "trial": "T029",
  "source": "fulltext",
  "arms": {
   "S-ketamine group": {
    "randomized": "61",
    "analysed": "60"
   },
   "Placebo group": {
    "randomized": "63",
    "analysed": "60"
   }
  },
  "depression": [
   {
    "measure": "HAMD-17",
    "day": -1,
    "form": "mean_sd",
    "location": "Table 2 (same values in Table 1, n = 60 per group)",
    "values": {
     "S-ketamine group": {
      "mean": "19.0",
      "sd": "3.59",
      "n": "60"
     },
     "Placebo group": {
      "mean": "19.5",
      "sd": "3.73",
      "n": "60"
     }
    }
   },
   {
    "measure": "HAMD-17",
    "day": 7,
    "form": "mean_sd",
    "location": "Table 2",
    "values": {
     "S-ketamine group": {
      "mean": "10.7",
      "sd": "4.80"
     },
     "Placebo group": {
      "mean": "15.5",
      "sd": "5.04"
     }
    }
   },
   {
    "measure": "HAMD-17",
    "day": 7,
    "form": "change_mean_sd",
    "location": "Table 2",
    "values": {
     "S-ketamine group": {
      "mean": "−8.8",
      "sd": "3.27"
     },
     "Placebo group": {
      "mean": "−3.5",
      "sd": "2.17"
     }
    }
   },
   {
    "measure": "PHQ-9",
    "day": -1,
    "form": "mean_sd",
    "location": "Table 2 (same values in Table 1, n = 60 per group)",
    "values": {
     "S-ketamine group": {
      "mean": "15.6",
      "sd": "2.65",
      "n": "60"
     },
     "Placebo group": {
      "mean": "15.2",
      "sd": "2.45",
      "n": "60"
     }
    }
   },
   {
    "measure": "PHQ-9",
    "day": 7,
    "form": "mean_sd",
    "location": "Table 2",
    "values": {
     "S-ketamine group": {
      "mean": "8.9",
      "sd": "3.45"
     },
     "Placebo group": {
      "mean": "13.0",
      "sd": "3.44"
     }
    }
   },
   {
    "measure": "PHQ-9",
    "day": 7,
    "form": "change_mean_sd",
    "location": "Table 2",
    "values": {
     "S-ketamine group": {
      "mean": "−6.7",
      "sd": "2.53"
     },
     "Placebo group": {
      "mean": "−2.2",
      "sd": "1.49"
     }
    }
   }
  ],
  "pain": [
   {
    "measure": "opioid use during hospital stay (morphine equivalents)",
    "day": 2,
    "form": "mean_sd",
    "location": "Table 3 ('Postoperative opioid used, mg'); Results text gives the same values as consumption within 2 days after surgery",
    "values": {
     "S-ketamine group": {
      "mean": "16.4",
      "sd": "5.9",
      "n": "60"
     },
     "Placebo group": {
      "mean": "23.9",
      "sd": "8.4",
      "n": "60"
     }
    }
   }
  ],
  "adverse_events": [
   {
    "window": "postoperative",
    "values": {
     "S-ketamine group": {
      "dizziness": "5"
     },
     "Placebo group": {
      "dizziness": "3"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2020-09-01",
   "end": "2022-03-01"
  },
  "registration": {
   "number": "NCT05506787",
   "date": null
  },
  "note": "Randomized 61 (S-ketamine) and 63 (placebo); 1 and 3 lost to follow-up; 60 per arm analysed. HAMD-17 and PHQ-9 at days 1, 3 and 30 appear only in Figure 2 (no printed values), so only baseline and day 7 (Table 2) are entered. Table 2 gives no n; the baseline n of 60 is Table 1's header, where the same baseline values are printed with '±' although its footnote says number (%) and median (IQR); Table 2 labels them Mean (SD). Change values are printed with a minus sign (U+2212). Table 2 also gives the treatment difference at day 7 as Mean (SE) and 95% CI: HAMD-17 −5.3 (0.50), −6.3 to −4.3; PHQ-9 −4.5 (0.38), −5.2 to −3.7. NRS (PACU, days 1, 2, 7) appears only in Figure 2d. Opioid: Methods describe opioid use throughout the hospital stay (morphine equivalents), but the Results text says the Table 3 values (16.4 [SD 5.9] vs 23.9 [SD 8.4]) are consumption within 2 days after surgery, so entered as day 2 (cumulative). Adverse events from Table 3 (timing not stated; read as postoperative): 'Dizzy' 5 (8.3%) vs 3 (5%) coded as dizziness; 'Dysphoria' 4 (6.7) vs 1 (1.7%), which the text calls irritability, not coded; nausea 3 (5%) vs 6 (10%). Enrollment period from the Results ('From 1 September 2020 to 1 March 2022, 151 patients ... were screened')."
 },
 {
  "trial": "T035",
  "source": "library",
  "arms": {
   "S-ketamine group": {
    "randomized": "40",
    "analysed": "39"
   },
   "Saline group": {
    "randomized": "40",
    "analysed": "38"
   }
  },
  "depression": [
   {
    "measure": "HADS-D",
    "day": -1,
    "form": "median_iqr",
    "location": "Table 1 (Preoperative HADS-D score)",
    "values": {
     "S-ketamine group": {
      "median": "5",
      "q1": "4",
      "q3": "7",
      "n": "39"
     },
     "Saline group": {
      "median": "6",
      "q1": "4",
      "q3": "7.8",
      "n": "38"
     }
    }
   },
   {
    "measure": "HADS-D",
    "day": 2,
    "form": "median_iqr",
    "location": "Table 4 (HADS-D score, 48 h)",
    "values": {
     "S-ketamine group": {
      "median": "4.0",
      "q1": "3.0",
      "q3": "6.0",
      "n": "39"
     },
     "Saline group": {
      "median": "6.0",
      "q1": "5.0",
      "q3": "8.0",
      "n": "38"
     }
    }
   },
   {
    "measure": "HADS-D",
    "day": 2,
    "form": "count",
    "definition": "HADS-D score >7",
    "location": "Table 4 (Proportion of depression)",
    "values": {
     "S-ketamine group": {
      "events": "6",
      "n": "39"
     },
     "Saline group": {
      "events": "5",
      "n": "38"
     }
    }
   }
  ],
  "pain": [
   {
    "measure": "NRS at rest",
    "day": 1,
    "form": "mean_sd",
    "location": "Results, Secondary Outcomes, text (24 h)",
    "values": {
     "S-ketamine group": {
      "mean": "2.5",
      "sd": "0.51"
     },
     "Saline group": {
      "mean": "2.8",
      "sd": "0.66"
     }
    }
   },
   {
    "measure": "NRS at rest",
    "day": 2,
    "form": "mean_sd",
    "location": "Results, Secondary Outcomes, text (48 h)",
    "values": {
     "S-ketamine group": {
      "mean": "2.1",
      "sd": "0.61"
     },
     "Saline group": {
      "mean": "2.6",
      "sd": "0.76"
     }
    }
   },
   {
    "measure": "NRS when coughing",
    "day": 1,
    "form": "mean_sd",
    "location": "Results, Secondary Outcomes, text (24 h)",
    "values": {
     "S-ketamine group": {
      "mean": "3.6",
      "sd": "0.59"
     },
     "Saline group": {
      "mean": "4.3",
      "sd": "0.64"
     }
    }
   },
   {
    "measure": "NRS when coughing",
    "day": 2,
    "form": "mean_sd",
    "location": "Results, Secondary Outcomes, text (48 h)",
    "values": {
     "S-ketamine group": {
      "mean": "3.3",
      "sd": "0.57"
     },
     "Saline group": {
      "mean": "3.7",
      "sd": "0.69"
     }
    }
   },
   {
    "measure": "rescue analgesia requirement (IM bucinnazine)",
    "day": 2,
    "form": "count",
    "definition": "patients given rescue analgesia (IM bucinnazine) during the 48 h study period",
    "location": "Table 4 (Rescue analgesia)",
    "values": {
     "S-ketamine group": {
      "events": "9",
      "n": "39"
     },
     "Saline group": {
      "events": "17",
      "n": "38"
     }
    }
   },
   {
    "measure": "rescue analgesia requirement (IM bucinnazine)",
    "day": 2,
    "form": "median_iqr",
    "location": "Table 4 (Bucinnazine requirements (mg), within the first 48 h)",
    "values": {
     "S-ketamine group": {
      "median": "0.0",
      "q1": "0.0",
      "q3": "75.0",
      "n": "39"
     },
     "Saline group": {
      "median": "0.0",
      "q1": "0.0",
      "q3": "100.0",
      "n": "38"
     }
    }
   }
  ],
  "adverse_events": [
   {
    "window": "overall",
    "values": {
     "S-ketamine group": {
      "visual": "1",
      "hallucination": "0",
      "dissociation": "0",
      "nightmare": "0",
      "dizziness": "0"
     },
     "Saline group": {
      "visual": "0",
      "hallucination": "0",
      "dissociation": "0",
      "nightmare": "0",
      "dizziness": "0"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2021-05",
   "end": "2021-12"
  },
  "registration": {
   "number": "ChiCTR2100046552",
   "date": null
  },
  "note": "Library copy of the PDF ('§' is the extraction's rendering of '±'). Randomized per arm from Statistical Analysis ('the authors enrolled 40 patients per group'; 80 enrolled, allocated 1:1); three were excluded after allocation (conversion to thoracotomy, refusal during follow-up, failure to complete follow-up), arms not stated; analysed 39 and 38 from the table headers. NRS at 24 and 48 h comes from the Results text, which says 'mean NRS scores' and lists the S-ketamine value first (the values agree with 'lower in the S-ketamine group'); Figure 2 plots them; no n. The text gives HADS-D at 48 h as 4 [3-6] v 6 [5-8] and bucinnazine as 0 [0-75] v 0 [0-100] mg; Table 4's decimals are taken. Rescue analgesia is entered twice: incidence (count) and bucinnazine dose (median, IQR), both within the first 48 h. Adverse events: Methods list S-ketamine adverse events as illusions, dissociation, diplopia, nystagmus, dizziness, dreams and urinary retention; the Results say 'Only 1 patient experienced an S-ketamine-related adverse event during the study' and the Discussion '1 case of diplopia that was self-limiting in the S-ketamine group'. The zeros come from those statements and are not printed as numerals (illusions coded as hallucination, dreams as nightmare). PONV 11 (28.2) vs 15 (39.5) not coded. The QoR-40 pain dimension at 48 h (32 (31.3-33) vs 31 (30-32)) is a recovery subscale and is not entered. Enrollment from the Results ('Between May 2021 and December 2021')."
 },
 {
  "trial": "T036",
  "source": "fulltext",
  "arms": {
   "K1 group": {
    "randomized": "26",
    "analysed": "26"
   },
   "K2 group": {
    "randomized": "26",
    "analysed": "26"
   },
   "K3 group": {
    "randomized": "26",
    "analysed": "26"
   },
   "C group": {
    "randomized": "26",
    "analysed": "26"
   }
  },
  "depression": [
   {
    "measure": "HADS depression subscale (HAD-D)",
    "day": -1,
    "form": "mean_sd",
    "location": "Table 2 (HAD-D Time_0 h, pre-operation)",
    "values": {
     "K1 group": {
      "mean": "7.4",
      "sd": "3.2",
      "n": "26"
     },
     "K2 group": {
      "mean": "7.4",
      "sd": "4.9",
      "n": "26"
     },
     "K3 group": {
      "mean": "7.4",
      "sd": "3.7",
      "n": "26"
     },
     "C group": {
      "mean": "7.4",
      "sd": "4.0",
      "n": "26"
     }
    }
   },
   {
    "measure": "HADS depression subscale (HAD-D)",
    "day": 1,
    "form": "mean_sd",
    "location": "Table 2 (HAD-D Time_24 h)",
    "values": {
     "K1 group": {
      "mean": "10.2",
      "sd": "4.3",
      "n": "26"
     },
     "K2 group": {
      "mean": "10.2",
      "sd": "5.0",
      "n": "26"
     },
     "K3 group": {
      "mean": "6.5",
      "sd": "4.1",
      "n": "26"
     },
     "C group": {
      "mean": "11.2",
      "sd": "3.7",
      "n": "26"
     }
    }
   },
   {
    "measure": "HADS depression subscale (HAD-D)",
    "day": 2,
    "form": "mean_sd",
    "location": "Table 2 (HAD-D Time_48 h)",
    "values": {
     "K1 group": {
      "mean": "10.3",
      "sd": "4.8",
      "n": "26"
     },
     "K2 group": {
      "mean": "10.3",
      "sd": "5.2",
      "n": "26"
     },
     "K3 group": {
      "mean": "5.7",
      "sd": "3.9",
      "n": "26"
     },
     "C group": {
      "mean": "10.8",
      "sd": "3.7",
      "n": "26"
     }
    }
   },
   {
    "measure": "HADS depression subscale (HAD-D)",
    "day": 3,
    "form": "mean_sd",
    "location": "Table 2 (HAD-D Time_72 h)",
    "values": {
     "K1 group": {
      "mean": "9.8",
      "sd": "4.7",
      "n": "26"
     },
     "K2 group": {
      "mean": "9.9",
      "sd": "5.4",
      "n": "26"
     },
     "K3 group": {
      "mean": "4.5",
      "sd": "3.3",
      "n": "26"
     },
     "C group": {
      "mean": "10.1",
      "sd": "3.8",
      "n": "26"
     }
    }
   }
  ],
  "pain": [],
  "adverse_events": [
   {
    "window": "emergence",
    "values": {
     "K1 group": {
      "agitation": "3",
      "dizziness": "0",
      "visual": "0",
      "hallucination": "0"
     },
     "K2 group": {
      "agitation": "3",
      "dizziness": "0",
      "visual": "0",
      "hallucination": "0"
     },
     "K3 group": {
      "agitation": "2",
      "dizziness": "0",
      "visual": "0",
      "hallucination": "0"
     },
     "C group": {
      "agitation": "1",
      "dizziness": "0",
      "visual": "0",
      "hallucination": "0"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2015-01",
   "end": "2017-10"
  },
  "registration": null,
  "note": "The source calls the control arm 'Control group' (the design's C group). 104 patients included, 26 per group (flow chart not in the text); every table has n = 26. HAD-D 'Time_0 h' is the pre-operation baseline (Methods: scored pre-operation and 24, 48 and 72 h post-operation; Results: 'before operation'), entered as day -1; 24, 48 and 72 h are days 1, 2 and 3. Superscripts (a, b) after K3 values are significance marks. VAS was recorded only 30 min after extubation and on leaving the recovery room (Table 3, medians (IQR) at 30 min: 2.0 (1.8–3.0), 2.0 (2.0–2.3), 2 (1.8–2.0), 2 (2.0–3.0) for K1, K2, K3, control), outside the day 1-2 window, so no pain entry. Adverse events at 30 min after extubation (Table 6): 'Dysphoria', which the Results call emergence agitation, coded as agitation (3, 3, 2, 1); Delirium 2 (7.7), 1 (3.8), 1 (3.8), 0 (0.0) not added to it (overlap unknown); at the time out of the operation room Dysphoria was 2, 2, 1, 1 and Delirium 0 in all groups. The dizziness, visual and hallucination zeros come from the text 'No dizziness, nausea, vomiting, diplopia, or other adverse reactions were found 30 min after extubation' (Methods list hallucination among recorded events); Table 6 contradicts the text on nausea ('Disgusting' 1 (3.8) in K1 and control). QoR-40 emotion and pain dimensions and HAD-A are not entered. Enrollment from Methods ('from Jan 2015 to Oct 2017'); the Results give no dates."
 },
 {
  "trial": "T045",
  "source": "fulltext",
  "arms": {
   "Esketamine group": {
    "randomized": "75",
    "analysed": "62"
   },
   "Control group (saline; PCIA without esketamine)": {
    "randomized": "75",
    "analysed": "61"
   }
  },
  "depression": [
   {
    "measure": "EPDS",
    "day": -1,
    "form": "median_iqr",
    "location": "Table 2 (Before surgery)",
    "values": {
     "Esketamine group": {
      "median": "7.0",
      "q1": "4.0",
      "q3": "10.0",
      "n": "62"
     },
     "Control group (saline; PCIA without esketamine)": {
      "median": "6.0",
      "q1": "3.0",
      "q3": "9.0",
      "n": "61"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": -1,
    "form": "count",
    "definition": "EPDS score ≥ 13 (PPD risk)",
    "location": "Table 2 (Before surgery)",
    "values": {
     "Esketamine group": {
      "events": "5",
      "n": "62"
     },
     "Control group (saline; PCIA without esketamine)": {
      "events": "6",
      "n": "61"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 3,
    "form": "median_iqr",
    "location": "Table 2 (3 days postpartum)",
    "values": {
     "Esketamine group": {
      "median": "6.0",
      "q1": "2.0",
      "q3": "8.0",
      "n": "62"
     },
     "Control group (saline; PCIA without esketamine)": {
      "median": "6.0",
      "q1": "3.0",
      "q3": "9.0",
      "n": "61"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 3,
    "form": "count",
    "definition": "EPDS score ≥ 13 (PPD risk)",
    "location": "Table 2 (3 days postpartum)",
    "values": {
     "Esketamine group": {
      "events": "4",
      "n": "62"
     },
     "Control group (saline; PCIA without esketamine)": {
      "events": "6",
      "n": "61"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 42,
    "form": "median_iqr",
    "location": "Table 2 (42 days postpartum)",
    "values": {
     "Esketamine group": {
      "median": "5.0",
      "q1": "2.0",
      "q3": "8.0",
      "n": "62"
     },
     "Control group (saline; PCIA without esketamine)": {
      "median": "5.5",
      "q1": "3.0",
      "q3": "8.0",
      "n": "61"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 42,
    "form": "count",
    "definition": "EPDS score ≥ 13 (PPD risk)",
    "location": "Table 2 (42 days postpartum)",
    "values": {
     "Esketamine group": {
      "events": "5",
      "n": "62"
     },
     "Control group (saline; PCIA without esketamine)": {
      "events": "8",
      "n": "61"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 90,
    "form": "median_iqr",
    "location": "Table 2 (3 months postpartum)",
    "values": {
     "Esketamine group": {
      "median": "5.0",
      "q1": "1.5",
      "q3": "8.0",
      "n": "60"
     },
     "Control group (saline; PCIA without esketamine)": {
      "median": "5.0",
      "q1": "2.0",
      "q3": "9.0",
      "n": "59"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 90,
    "form": "count",
    "definition": "EPDS score ≥ 13 (PPD risk)",
    "location": "Table 2 (3 months postpartum)",
    "values": {
     "Esketamine group": {
      "events": "6",
      "n": "60"
     },
     "Control group (saline; PCIA without esketamine)": {
      "events": "7",
      "n": "59"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 180,
    "form": "median_iqr",
    "location": "Table 2 (6 months postpartum)",
    "values": {
     "Esketamine group": {
      "median": "4.0",
      "q1": "0.0",
      "q3": "8.0",
      "n": "57"
     },
     "Control group (saline; PCIA without esketamine)": {
      "median": "5.5",
      "q1": "2.0",
      "q3": "9.0",
      "n": "57"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 180,
    "form": "count",
    "definition": "EPDS score ≥ 13 (PPD risk)",
    "location": "Table 2 (6 months postpartum)",
    "values": {
     "Esketamine group": {
      "events": "4",
      "n": "57"
     },
     "Control group (saline; PCIA without esketamine)": {
      "events": "6",
      "n": "57"
     }
    }
   }
  ],
  "pain": [
   {
    "measure": "NRS at rest",
    "day": 1,
    "form": "median_iqr",
    "location": "Table 4 (POD 1)",
    "values": {
     "Esketamine group": {
      "median": "2.0",
      "q1": "1.0",
      "q3": "2.0",
      "n": "62"
     },
     "Control group (saline; PCIA without esketamine)": {
      "median": "2.0",
      "q1": "1.0",
      "q3": "2.0",
      "n": "61"
     }
    }
   },
   {
    "measure": "NRS at rest",
    "day": 2,
    "form": "median_iqr",
    "location": "Table 4 (POD 2)",
    "values": {
     "Esketamine group": {
      "median": "1.0",
      "q1": "0.0",
      "q3": "1.0",
      "n": "62"
     },
     "Control group (saline; PCIA without esketamine)": {
      "median": "1.0",
      "q1": "1.0",
      "q3": "1.0",
      "n": "61"
     }
    }
   },
   {
    "measure": "NRS during coughing",
    "day": 1,
    "form": "median_iqr",
    "location": "Table 4 (POD 1)",
    "values": {
     "Esketamine group": {
      "median": "4.0",
      "q1": "3.0",
      "q3": "4.0",
      "n": "62"
     },
     "Control group (saline; PCIA without esketamine)": {
      "median": "4.0",
      "q1": "4.0",
      "q3": "5.0",
      "n": "61"
     }
    }
   },
   {
    "measure": "NRS during coughing",
    "day": 2,
    "form": "median_iqr",
    "location": "Table 4 (POD 2)",
    "values": {
     "Esketamine group": {
      "median": "3.0",
      "q1": "2.0",
      "q3": "3.0",
      "n": "62"
     },
     "Control group (saline; PCIA without esketamine)": {
      "median": "3.0",
      "q1": "3.0",
      "q3": "4.0",
      "n": "61"
     }
    }
   },
   {
    "measure": "cumulative sufentanil consumption 0-48 h",
    "day": 1,
    "form": "mean_sd",
    "location": "Results 3.3, text (first 24 h)",
    "values": {
     "Esketamine group": {
      "mean": "37.8",
      "sd": "7.4"
     },
     "Control group (saline; PCIA without esketamine)": {
      "mean": "47.3",
      "sd": "8.3"
     }
    }
   },
   {
    "measure": "cumulative sufentanil consumption 0-48 h",
    "day": 2,
    "form": "mean_sd",
    "location": "Results 3.3, text (48 h)",
    "values": {
     "Esketamine group": {
      "mean": "74.5",
      "sd": "12.3"
     },
     "Control group (saline; PCIA without esketamine)": {
      "mean": "86.4",
      "sd": "13.5"
     }
    }
   }
  ],
  "adverse_events": [
   {
    "window": "intraoperative",
    "values": {
     "Esketamine group": {
      "hallucination": "3",
      "nightmare": "1",
      "dizziness": "10"
     },
     "Control group (saline; PCIA without esketamine)": {
      "hallucination": "0",
      "nightmare": "0",
      "dizziness": "2"
     }
    }
   },
   {
    "window": "postoperative",
    "values": {
     "Esketamine group": {
      "hallucination": "2",
      "nightmare": "1",
      "dizziness": "6"
     },
     "Control group (saline; PCIA without esketamine)": {
      "hallucination": "0",
      "nightmare": "0",
      "dizziness": "4"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2021-05",
   "end": "2021-12"
  },
  "registration": {
   "number": "ChiCTR2100046049",
   "date": null
  },
  "note": "150 randomized; 75 per arm from the sample-size section ('we enrolled 75 patients in each group'), consistent with exclusions of 13 (6 withdrew consent, 7 lost) and 14 (8 withdrew, 6 lost); 62 and 61 analysed. The source calls the control arm 'control group' (saline infusion; PCIA without esketamine). EPDS baseline was a face-to-face interview one day before surgery; follow-up online at 3 days, 42 days, 3 months and 6 months (entered as days 3, 42, 90, 180); the 3- and 6-month n come from Table 2's subheadings, the others from its header. Methods state the PPD cut-off as 'EPDS score > 12'; Table 2 prints '≥ 13'. EPDS area under the curve 130.2 ± 115.9 vs 152.2 ± 126.6 not entered; EPDS-3A anxiety not entered. Sufentanil 0-24 h and 0-48 h from the Results text (no n); 0-12, 12-24 and 24-48 h only in Figure 2. Adverse events from Table 4; the Results text calls intraoperative dizziness 'significantly lower in the esketamine group' while printing 16.1 % vs 3.3 %, which matches Table 4's 10 (esketamine) vs 2 (control), so the table is taken. Nausea, vomiting and pruritus not coded. Enrollment period from Methods (trial 'conducted ... between May 2021 and December 2021'); the Results give no dates."
 },
 {
  "trial": "T071",
  "source": "fulltext",
  "arms": {
   "Ketamine": {
    "randomized": "16",
    "analysed": null
   },
   "Normal saline placebo": {
    "randomized": "16",
    "analysed": null
   }
  },
  "depression": [
   {
    "measure": "MADRS",
    "day": -1,
    "form": "median_iqr",
    "location": "Table 1 (Preoperative MADRS); same in Results text",
    "values": {
     "Ketamine": {
      "median": "14.5",
      "q1": "9",
      "q3": "21",
      "n": "16"
     },
     "Normal saline placebo": {
      "median": "12.5",
      "q1": "6",
      "q3": "23.5",
      "n": "16"
     }
    }
   },
   {
    "measure": "MADRS",
    "day": 4,
    "form": "median_iqr",
    "location": "Results, Collection of clinical outcomes, text (post-infusion day 4)",
    "values": {
     "Ketamine": {
      "median": "4",
      "q1": "2",
      "q3": "16"
     },
     "Normal saline placebo": {
      "median": "6",
      "q1": "3.5",
      "q3": "12"
     }
    }
   }
  ],
  "pain": [
   {
    "measure": "total opioid dose (oral morphine equivalents) to 07:00 post-infusion day 2",
    "day": 2,
    "form": "median_iqr",
    "location": "Results, Collection of clinical outcomes, text",
    "values": {
     "Ketamine": {
      "median": "78.2",
      "q1": "52.5",
      "q3": "219"
     },
     "Normal saline placebo": {
      "median": "118",
      "q1": "32.2",
      "q3": "179.5"
     }
    }
   }
  ],
  "adverse_events": [
   {
    "window": "postoperative",
    "values": {
     "Ketamine": {
      "dizziness": "5",
      "visual": "2",
      "agitation": "0"
     },
     "Normal saline placebo": {
      "dizziness": "2",
      "visual": "1",
      "agitation": "1"
     }
    }
   }
  ],
  "blinding_check": {
   "who": "participants",
   "when": "1 day after the infusion",
   "location": "Results, Study medication administration",
   "values": {
    "Ketamine": {
     "correct": "7",
     "n": "16"
    },
    "Normal saline placebo": {
     "correct": "7",
     "n": "16"
    }
   }
  },
  "enrollment": {
   "start": "2022-05-05",
   "end": "2023-02-21"
  },
  "registration": {
   "number": "NCT05233566",
   "date": "2022-02-10"
  },
  "note": "Feasibility trial; the study drug started after extubation, so days are the source's post-infusion days (infusion delayed to POD 1 for three control participants and to POD 2 for one ketamine participant). 16 per arm randomized (Table 1 N); no per-arm analysed n (MADRS completed at 170 of 192 planned assessments). MADRS on days 1, 2, 7 and 14 appears only in Figure 4 (box plots); the day-4 medians (IQR) come from the Results text, with no n. Median regression difference in change from baseline to day 4, adjusted for baseline: −1.00 (95% CI −3.23 to 1.73); post hoc subgroup with baseline MADRS >6: −1.76 (−3.63 to 2.77). Pain scores appear only in supplementary figures. Opioid: 'cumulative postoperative opioid exposure between the start of the study medication infusion and 07:00 am on post-infusion day 2', printed as 78.2 (IQR 52.5–219) vs 118 (IQR 32.2–179.5) oral morphine milligram equivalents; the central value is read as a median because an IQR is given; entered as day 2 per the design. Adverse events from Table 2, during the infusion (3 control participants refused or could not be interviewed, so control rows total 13): Dizziness 5 (31) vs 2 (15); Seeing double 2 (12) vs 1 (8) as visual; RASS '1 (Restless)' 0 (0) vs 1 (8) as agitation. Not coded because a count would need summing across scale levels: BPRS hallucinatory behaviour, ketamine 16 (100) no symptoms with 0 (0) at scores 2 and 3, control 11 (85) no symptoms, 1 (8) at score 2 and 1 (8) at score 3; CADSS-6, ketamine 0: 9 (56), 1: 3 (19), 2: 1 (6), 3: 1 (6), 4: 2 (12), 6: 0 (0), control 0: 11 (85), 4: 1 (8), 6: 1 (8); BPRS conceptual disorganisation, ketamine 1 (6) at score 3, control 2 (15) at score 2. Blinding: 'seven out of 16 participants in the ketamine group and seven out of 16 participants in the control group correctly guessed which treatment they received'. One control participant died on postoperative day 13. Enrollment: participants included between 5 May 2022 and 21 February 2023 (recruitment 11 April 2022 to 17 February 2023). Registration date is the 'first posted' date."
 },
 {
  "trial": "T076",
  "source": "fulltext",
  "arms": {
   "Sufentanil group (S1)": {
    "randomized": "45",
    "analysed": "44"
   },
   "Sufentanil + 0.25 mg/kg esketamine group (SK1)": {
    "randomized": "45",
    "analysed": "42"
   },
   "Sufentanil + 0.5 mg/kg esketamine group (SK2)": {
    "randomized": "45",
    "analysed": "41"
   }
  },
  "depression": [
   {
    "measure": "HAM-D",
    "day": -1,
    "form": "mean_sd",
    "location": "Table 2 (1d before surgery)",
    "values": {
     "Sufentanil group (S1)": {
      "mean": "14.02",
      "sd": "1.95",
      "n": "44"
     },
     "Sufentanil + 0.25 mg/kg esketamine group (SK1)": {
      "mean": "14.31",
      "sd": "2.29",
      "n": "42"
     },
     "Sufentanil + 0.5 mg/kg esketamine group (SK2)": {
      "mean": "14.51",
      "sd": "2.23",
      "n": "41"
     }
    }
   },
   {
    "measure": "HAM-D",
    "day": 1,
    "form": "mean_sd",
    "location": "Table 2 (1d after surgery)",
    "values": {
     "Sufentanil group (S1)": {
      "mean": "14.18",
      "sd": "1.97",
      "n": "44"
     },
     "Sufentanil + 0.25 mg/kg esketamine group (SK1)": {
      "mean": "13.38",
      "sd": "1.67",
      "n": "42"
     },
     "Sufentanil + 0.5 mg/kg esketamine group (SK2)": {
      "mean": "12.41",
      "sd": "1.73",
      "n": "41"
     }
    }
   },
   {
    "measure": "HAM-D",
    "day": 2,
    "form": "mean_sd",
    "location": "Table 2 (2d after surgery)",
    "values": {
     "Sufentanil group (S1)": {
      "mean": "12.30",
      "sd": "1.75",
      "n": "44"
     },
     "Sufentanil + 0.25 mg/kg esketamine group (SK1)": {
      "mean": "11.55",
      "sd": "1.73",
      "n": "42"
     },
     "Sufentanil + 0.5 mg/kg esketamine group (SK2)": {
      "mean": "10.73",
      "sd": "1.41",
      "n": "41"
     }
    }
   },
   {
    "measure": "HAM-D",
    "day": 5,
    "form": "mean_sd",
    "location": "Table 2 (5d after surgery)",
    "values": {
     "Sufentanil group (S1)": {
      "mean": "10.57",
      "sd": "1.66",
      "n": "44"
     },
     "Sufentanil + 0.25 mg/kg esketamine group (SK1)": {
      "mean": "9.64",
      "sd": "1.50",
      "n": "42"
     },
     "Sufentanil + 0.5 mg/kg esketamine group (SK2)": {
      "mean": "9.49",
      "sd": "1.27",
      "n": "41"
     }
    }
   },
   {
    "measure": "HAM-D",
    "day": 7,
    "form": "mean_sd",
    "location": "Table 2 (7d after surgery)",
    "values": {
     "Sufentanil group (S1)": {
      "mean": "8.68",
      "sd": "1.14",
      "n": "44"
     },
     "Sufentanil + 0.25 mg/kg esketamine group (SK1)": {
      "mean": "8.52",
      "sd": "1.29",
      "n": "42"
     },
     "Sufentanil + 0.5 mg/kg esketamine group (SK2)": {
      "mean": "8.49",
      "sd": "0.95",
      "n": "41"
     }
    }
   }
  ],
  "pain": [
   {
    "measure": "VAS (1, 6, 12, 24, 48 h)",
    "day": 1,
    "form": "mean_sd",
    "location": "Table 2 (24 h after surgery)",
    "values": {
     "Sufentanil group (S1)": {
      "mean": "2.43",
      "sd": "0.50",
      "n": "44"
     },
     "Sufentanil + 0.25 mg/kg esketamine group (SK1)": {
      "mean": "2.14",
      "sd": "0.52",
      "n": "42"
     },
     "Sufentanil + 0.5 mg/kg esketamine group (SK2)": {
      "mean": "2.02",
      "sd": "0.42",
      "n": "41"
     }
    }
   },
   {
    "measure": "VAS (1, 6, 12, 24, 48 h)",
    "day": 2,
    "form": "mean_sd",
    "location": "Table 2 (48 h after surgery)",
    "values": {
     "Sufentanil group (S1)": {
      "mean": "1.93",
      "sd": "0.50",
      "n": "44"
     },
     "Sufentanil + 0.25 mg/kg esketamine group (SK1)": {
      "mean": "1.64",
      "sd": "0.48",
      "n": "42"
     },
     "Sufentanil + 0.5 mg/kg esketamine group (SK2)": {
      "mean": "1.54",
      "sd": "0.50",
      "n": "41"
     }
    }
   },
   {
    "measure": "PCIA button presses over 48 h",
    "day": 2,
    "form": "mean_sd",
    "location": "Table 4 (PCIA button presses number)",
    "values": {
     "Sufentanil group (S1)": {
      "mean": "6.98",
      "sd": "0.63",
      "n": "44"
     },
     "Sufentanil + 0.25 mg/kg esketamine group (SK1)": {
      "mean": "6.67",
      "sd": "0.65",
      "n": "42"
     },
     "Sufentanil + 0.5 mg/kg esketamine group (SK2)": {
      "mean": "6.46",
      "sd": "0.55",
      "n": "41"
     }
    }
   }
  ],
  "adverse_events": [
   {
    "window": "postoperative",
    "values": {
     "Sufentanil group (S1)": {
      "dizziness": "5",
      "hallucination": "3"
     },
     "Sufentanil + 0.25 mg/kg esketamine group (SK1)": {
      "dizziness": "4",
      "hallucination": "5"
     },
     "Sufentanil + 0.5 mg/kg esketamine group (SK2)": {
      "dizziness": "5",
      "hallucination": "5"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2022-11",
   "end": "2023-12"
  },
  "registration": {
   "number": "ChiCTR2200065198",
   "date": "2022-10-31"
  },
  "note": "Randomized 45 per arm from the sample-size section ('we recruited 45 patients per group (total N = 135)'); losses: S1 1 lost; SK1 2 lost and 1 discontinued (postoperative bleeding); SK2 2 lost, 1 withdrew, 1 discontinued (acute kidney injury); 127 analysed (44, 42, 41). The Methods' 'randomly allocated ... (S1, n = 44; SK1, n = 42; SK2, n = 41)' are the analysed numbers. Superscript letters (a, b, c) printed after values are significance marks and are dropped. HAM-D '1d before surgery' entered as day -1. VAS at 1, 6 and 12 h not entered (outside the day 1-2 window); intraoperative remifentanil 0.87 ± 0.22, 0.76 ± 0.20, 0.75 ± 0.22 mg (day 0) not entered. Adverse events (Table 4, collected during the postoperative 48 h): nausea, vomiting and respiratory depression not coded. Enrollment from Methods ('from November 2022 to December 2023'); the Results give no dates."
 },
 {
  "trial": "T092",
  "source": "fulltext",
  "arms": {
   "Esketamine group (group E)": {
    "randomized": "40",
    "analysed": "40"
   },
   "Saline group (group C)": {
    "randomized": "40",
    "analysed": "39"
   }
  },
  "depression": [],
  "pain": [],
  "adverse_events": [
   {
    "window": "postoperative",
    "values": {
     "Esketamine group (group E)": {
      "agitation": "1",
      "dizziness": "1"
     },
     "Saline group (group C)": {
      "agitation": "1",
      "dizziness": "1"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2023-02",
   "end": "2023-06"
  },
  "registration": {
   "number": "ChiCTR2200063302",
   "date": null
  },
  "note": "SDS (and SAS) before and after surgery appear only in Figure 3 (mean ± SD bars, no printed values), so there is no depression entry. VAS after recovery (Table 1: 0.98 ± 0.73 vs 0.97 ± 0.87) is on the day of surgery, outside the day 1-2 window. One control patient withdrew (refused to continue); 40 and 39 analysed. Adverse events (Table 3): Restlessness 1 (2.5) vs 1 (2.6) coded as agitation; Vertigo 1 (2.5) vs 1 (2.6) coded as dizziness; nausea and vomiting 4 (10) vs 3 (7.7), bradycardia and tachycardia not coded. Enrollment from Methods (surgery 'between February 2023 and June 2023'); the registration is described as prospective but its date is not given."
 },
 {
  "trial": "T101",
  "source": "fulltext",
  "arms": {
   "Esketamine group": {
    "randomized": "90",
    "analysed": "86"
   },
   "Placebo group": {
    "randomized": "90",
    "analysed": "87"
   }
  },
  "depression": [
   {
    "measure": "PHQ-8",
    "day": -1,
    "form": "median_iqr",
    "location": "Table 1 (Preoperative status, PHQ-8 score)",
    "values": {
     "Esketamine group": {
      "median": "6",
      "q1": "5",
      "q3": "9",
      "n": "86"
     },
     "Placebo group": {
      "median": "7.0",
      "q1": "4",
      "q3": "10",
      "n": "87"
     }
    }
   },
   {
    "measure": "PHQ-8",
    "day": 3,
    "form": "median_iqr",
    "location": "Table 3 (PHQ-8 score POD3)",
    "values": {
     "Esketamine group": {
      "median": "5",
      "q1": "3",
      "q3": "8",
      "n": "86"
     },
     "Placebo group": {
      "median": "5",
      "q1": "3",
      "q3": "8",
      "n": "87"
     }
    }
   },
   {
    "measure": "PHQ-8",
    "day": 30,
    "form": "median_iqr",
    "location": "Table 3 (PHQ-8 score POD30)",
    "values": {
     "Esketamine group": {
      "median": "5",
      "q1": "2",
      "q3": "8"
     },
     "Placebo group": {
      "median": "6",
      "q1": "3",
      "q3": "10"
     }
    }
   }
  ],
  "pain": [
   {
    "measure": "NRS pain",
    "day": 1,
    "form": "median_iqr",
    "location": "Table 3 (NRS score at rest POD1)",
    "values": {
     "Esketamine group": {
      "median": "1",
      "q1": "0",
      "q3": "2"
     },
     "Placebo group": {
      "median": "1",
      "q1": "0",
      "q3": "2"
     }
    }
   },
   {
    "measure": "NRS pain",
    "day": 2,
    "form": "median_iqr",
    "location": "Table 3 (NRS score at rest POD2)",
    "values": {
     "Esketamine group": {
      "median": "0",
      "q1": "0",
      "q3": "1"
     },
     "Placebo group": {
      "median": "0",
      "q1": "0",
      "q3": "1"
     }
    }
   },
   {
    "measure": "NRS score at cough",
    "day": 1,
    "form": "median_iqr",
    "location": "Table 3 (NRS score at cough POD1)",
    "values": {
     "Esketamine group": {
      "median": "3",
      "q1": "1",
      "q3": "4"
     },
     "Placebo group": {
      "median": "2",
      "q1": "1",
      "q3": "4"
     }
    }
   },
   {
    "measure": "NRS score at cough",
    "day": 2,
    "form": "median_iqr",
    "location": "Table 3 (NRS score at cough POD2)",
    "values": {
     "Esketamine group": {
      "median": "2",
      "q1": "1",
      "q3": "3"
     },
     "Placebo group": {
      "median": "2",
      "q1": "1",
      "q3": "3"
     }
    }
   }
  ],
  "adverse_events": [],
  "blinding_check": null,
  "enrollment": {
   "start": "2024-08-05",
   "end": "2025-06-30"
  },
  "registration": {
   "number": "NCT06530706",
   "date": "2024-07-31"
  },
  "note": "180 randomized (90 and 90); 88 per arm received the allocated intervention; 86 and 87 analysed (primary endpoint data). PHQ-8 baseline from Table 1 'Preoperative status' (collected after consent, before surgery). Table 3 adjusted mean differences (ANCOVA): PHQ-8 POD3 0 (−1 to 1), POD30 −2 (−3 to −1). POD30 n is left out: Table 3's header says n=86 and n=87, but HAMA ≤ 7 at POD30 has denominators 84 and 85. The design lists one pain measure, 'NRS pain'; the source reports NRS at rest and at cough (Table 3, exploratory): rest is entered as 'NRS pain' and cough under the source's name 'NRS score at cough'. Their n is left out because Table 4's POD1 and POD2 nausea denominators are 84 and 85 in the esketamine group. NRS after extubation 0 [0, 2] in both groups (day 0) not entered. No psychotomimetic adverse events are reported: Table 4 covers hypotension, vasopressors, hypertension, antihypertensives, nausea and vomiting, and 'No serious adverse events were reported in either group'. Enrollment from the Results ('from 5 Aug, 2024 to 30 Jun, 2025')."
 }
]